Hutsell TC - Search Results

1

Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study.

Kaul S, Makkar RR, Nakamura M, Litvack FI, Shah PK, Forrester JS, Hutsell TC, Eigler NL. Kaul S, et al. Among authors: hutsell tc. Circulation. 1996 Nov 1;94(9):2228-34. doi: 10.1161/01.cir.94.9.2228. Circulation. 1996. PMID: 8901676

2

Local Delivery of an Ultra-short-acting Nitric Oxide-releasing Compound, DMHD/NO, Is Highly Effective in Inhibiting Acute Platelet-Thrombus Formation on Injured Arterial Strips.

Kaul S, Naqvi TZ, Fishbein MC, Cercek B, Badimon JJ, Hutsell TC, Thomas S, Molloy M, Shah PK. Kaul S, et al. Among authors: hutsell tc. J Cardiovasc Pharmacol Ther. 1997 Jul;2(3):181-194. doi: 10.1177/107424849700200305. J Cardiovasc Pharmacol Ther. 1997. PMID: 10684457

3

Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro.

Mooradian DL, Hutsell TC, Keefer LK. Mooradian DL, et al. Among authors: hutsell tc. J Cardiovasc Pharmacol. 1995 Apr;25(4):674-8. J Cardiovasc Pharmacol. 1995. PMID: 7596138

4

Nitric oxide donors: a continuing opportunity in drug design.

Hanson SR, Hutsell TC, Keefer LK, Mooradian DL, Smith DJ. Hanson SR, et al. Among authors: hutsell tc. Adv Pharmacol. 1995;34:383-98. doi: 10.1016/s1054-3589(08)61099-6. Adv Pharmacol. 1995. PMID: 8562447 Review. No abstract available.

5

Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension.

Hampl V, Tristani-Firouzi M, Hutsell TC, Archer SL. Hampl V, et al. Among authors: hutsell tc. Cardiovasc Res. 1996 Jan;31(1):55-62. Cardiovasc Res. 1996. PMID: 8849589

6

Nitric oxide-releasing polymers containing the [N(O)NO]- group.

Smith DJ, Chakravarthy D, Pulfer S, Simmons ML, Hrabie JA, Citro ML, Saavedra JE, Davies KM, Hutsell TC, Mooradian DL, Hanson SR, Keefer LK. Smith DJ, et al. Among authors: hutsell tc. J Med Chem. 1996 Mar 1;39(5):1148-56. doi: 10.1021/jm950652b. J Med Chem. 1996. PMID: 8676352

7

Boundary layer infusion of nitric oxide reduces early smooth muscle cell proliferation in the endarterectomized canine artery.

Chen C, Hanson SR, Keefer LK, Saavedra JE, Davies KM, Hutsell TC, Hughes JD, Ku DN, Lumsden AB. Chen C, et al. Among authors: hutsell tc. J Surg Res. 1997 Jan;67(1):26-32. doi: 10.1006/jsre.1996.4915. J Surg Res. 1997. PMID: 9070177

8

Targeted Coronary Thrombolysis via "Pericardial" Administration of Lytic Agents?

Przyklenk K, Hutsell TC, Hata K, Whittaker P. Przyklenk K, et al. Among authors: hutsell tc. J Thromb Thrombolysis. 1998 Sep;6(2):83-88. doi: 10.1023/A:1008870700908. J Thromb Thrombolysis. 1998. PMID: 10751788 No abstract available.

9

Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.

Karim A, Zagarella J, Hutsell TC, Dooley M. Karim A, et al. Among authors: hutsell tc. Clin Pharmacol Ther. 1976 Feb;19(2):177-82. doi: 10.1002/cpt1976192177. Clin Pharmacol Ther. 1976. PMID: 1261155

10

Spironolactone. II. Bioavailability.

Karim A, Zagarella J, Hutsell TC, Chao A, Baltes BJ. Karim A, et al. Among authors: hutsell tc. Clin Pharmacol Ther. 1976 Feb;19(2):170-6. doi: 10.1002/cpt1976192170. Clin Pharmacol Ther. 1976. PMID: 1261154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page